Targeting bacterial membrane function: An underexploited mechanism for treating persistent infections

Nature Reviews Microbiology

Volumn 9, Issue 1, 2011, Pages 62-75

  Hurdle, Julian G ^a,b   O'Neill, Alex J ^c   Chopra, Ian ^c   Lee, Richard E ^b  

^a UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; BETA LACTAM; CARDIOLIPIN; CLOFAZIMINE DERIVATIVE; DALBAVANCIN; DAPTOMYCIN; METRONIDAZOLE; NITAZOXANIDE; NITROFURAN; NITROIMIDAZOLE; ORITAVANCIN; PHOSPHATIDYLGLYCEROL; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE INHIBITOR; PYRAZINAMIDE; TELAVANCIN; VANCOMYCIN;

BACTERIAL GROWTH; BACTERIAL MEMBRANE; BIOFILM; CHLAMYDIA TRACHOMATIS; ENERGY METABOLISM; LACTOBACILLUS REUTERI; MEMBRANE DAMAGE; MEMBRANE POTENTIAL; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TARGET CELL;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CELL MEMBRANE; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL;

BACTERIA (MICROORGANISMS);

EID: 78650293305     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro2474     Document Type: Review

References (166)

1. Coates, A. R. & Hu, Y. Targeting non-multiplying organisms as a way to develop novel antimicrobials. Trends Pharmacol. Sci. 29, 143-150 (2008).
2. Levin, B. R. & Rozen, D. E. Non-inherited antibiotic resistance. Nature Rev. Microbiol. 4, 556-562 (2006).
3. Chopra, I., Hesse, L. & O'Neill, A. J. Exploiting current understanding of antibiotic action for discovery of new drugs. J. Appl. Microbiol. 92, S4-S15 (2002).
4. Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318-1322 (1999).
5. Wright, J. A. & Nair, S. P. Interaction of staphylococci with bone. Int. J. Med. Microbiol. 300, 193-204 (2010).
6. Lewis, K. Persister cells, dormancy and infectious disease. Nature Rev. Microbiol. 5, 48-56 (2007).
7. Stewart, G. R., Robertson, B. D. & Young, D. B. Tuberculosis: a problem with persistence. Nature Rev. Microbiol. 1, 97-105 (2003).
8. Mader, J. T., Shirtliff, M. E., Bergquist, S. C. & Calhoun, J. Antimicrobial treatment of chronic osteomyelitis. Clin. Orthop. Relat. Res. 360, 47-65 (1999).
9. Baddour, L. M. et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111, e394-e434 (2005).
10. Coates, A., Hu, Y., Bax, R. & Page, C. The future challenges facing the development of new antimicrobial drugs. Nature Rev. Drug Discov. 1, 895-910 (2002).
11. O'Neill, A. J. in Emerging Trends in Antibacterial Discovery Ch. 9 (eds Miller, A. A. & Miller, P. F.) (Horizon Scientific, in the press).
12. Roveta, S., Schito, A. M., Marchese, A. & Schito, G. C. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents 30, 415-421 (2007).
13. Hu, Y., Coates, A. R. & Mitchison, D. A. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 12, 69-73 (2008).
14. Lenaerts, A. J. et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49, 2294-2301 (2005).
15. Rose, W. E. & Poppens, P. T. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 63, 485-488 (2009).
16. Boshoff, H. I. & Barry, C. E. 3rd. Tuberculosis - metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70-80 (2005).
17. Stewart, P. S. & Franklin, M. J. Physiological heterogeneity in biofilms. Nature Rev. Microbiol. 6, 199-210 (2008).
18. Yoon, S. S. et al. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev. Cell 3, 593-603 (2002).
19. Resch, A., Rosenstein, R., Nerz, C. & Gotz, F. Differential gene expression profiling of Staphylococcus aureus cultivated under biofilm and planktonic conditions. Appl. Environ. Microbiol. 71, 2663-2676 (2005).
20. Falsetta, M. L., McEwan, A. G., Jennings, M. P. & Apicella, M. A. Anaerobic metabolism occurs in the substratum of gonococcal biofilms and may be sustained in part by nitric oxide. Infect. Immun. 78, 2320-2328 (2010).
21. Barry, C. E., 3rd. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Rev. Microbiol. 7, 845-855 (2009).
22. Ojha, A. K. et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol. Microbiol. 69, 164-174 (2008).
23. Bigger, J. W. Treatment of staphylococcal infections with penicillin. Lancet 244, 497-500 (1944).
24. Tuomanen, E., Durack, D. T. & Tomasz, A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob. Agents Chemother. 30, 521-527 (1986).
25. Zhang, Y. M. & Rock, C. O. Transcriptional regulation in bacterial membrane lipid synthesis. J. Lipid Res. 50, S115-S119 (2009).
26. Nolan, E. M. & Walsh, C. T. How nature morphs peptide scaffolds into antibiotics. Chembiochem. 10, 34-53 (2009).
27. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29-40 (2007).
28. Verkleij, A. J. et al. The asymmetric distribution of phospholipids in the human red cell membrane. A combined study using phospholipases and freeze-etch electron microscopy. Biochim. Biophys. Acta 323, 178-193 (1973).
29. Straus, S. K. & Hancock, R. E. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758, 1215-1223 (2006).
30. Domenech, O., Dufrene, Y. F., Van Bambeke, F., Tukens, P. M. & Mingeot-Leclercq, M. P. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. Biochim. Biophys. Acta 1798, 1876-1885 (2010).
31. Domenech, O. et al. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. Biochim. Biophys. Acta 1788, 1832-1840 (2009).
32. Zhang, L., Dhillon, P., Yan, H., Farmer, S. & Hancock, R. E. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 3317-3321 (2000).
33. Kashket, E. R. Proton motive force in growing Streptococcus lactis and Staphylococcus aureus cells under aerobic and anaerobic conditions. J. Bacteriol. 146, 369-376 (1981).
34. Kashket, E. R. Effects of aerobiosis and nitrogen source on the proton motive force in growing Escherichia coli and Klebsiella pneumoniae cells. J. Bacteriol. 146, 377-384 (1981).
35. Rao, S. P., Alonso, S., Rand, L., Dick, T. & Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Nat. Acad. Sci. USA 105, 11945-11950 (2008).
36. Vandal, O. H., Nathan, C. F. & Ehrt, S. Acid resistance in Mycobacterium tuberculosis. J. Bacteriol. 191, 4714-4721 (2009).
37. Hu, Y., Shamaei-Tousi, A., Liu, Y. & Coates, A. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections. PLoS ONE 5, e11818 (2010).
38. Pamp, S. J., Gjermansen, M., Johansen, H. K. & Tolker-Nielsen, T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol. Microbiol. 68, 223-240 (2008).
39. McPhee, J. B., Lewenza, S. & Hancock, R. E. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 50, 205-217 (2003).
40. Guskey, M. T. & Tsuji, B. T. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 30, 80-94 (2010).
41. Raad, I. et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51, 1656-1660 (2007).
42. LaPlante, K. L. & Mermel, L. A. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol. Dial. Transplant. 22, 2239-2246 (2007).
43. Warren, R. E. Daptomycin in endocarditis and bacteraemia: a British perspective. J. Antimicrob. Chemother. 62, 25-33 (2008).
44. Weiss, E. C. et al. Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo. Antimicrob. Agents Chemother. 53, 4096-4102 (2009).
45. Mikkelsen, H., Duck, Z., Lilley, K. S. & Welch, M. Interrelationships between colonies, biofilms, and planktonic cells of Pseudomonas aeruginosa. J. Bacteriol. 189, 2411-2416 (2007).
46. Lewis, K. Persister Cells. Annu. Rev. Microbiol. 64, 357-372 (2010).
47. Chiu, T. H. & Hung., S. A. Effect of age on the membrane lipid composition of Streptococcus sanguis. Biochim. Biophys. Acta 558, 267-272 (1979).
48. Zhang, Y. M. & Rock, C. O. Membrane lipid homeostasis in bacteria. Nature Rev. Microbiol. 6, 222-233 (2008).
49. Mascio, C. T., Alder, J. D. & Silverman, J. A. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51, 4255-4260 (2007).
50. Ooi, N. et al. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J. Antimicrob. Chemother. 65, 72-78 (2010).
51. Belley, A. et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob. Agents Chemother. 53, 918-925 (2009).
52. LaPlante, K. L. & Mermel, L. A. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob. Agents Chemother. 53, 3166-3169 (2009).
53. Darouiche, R. O. & Mansouri, M. D. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J. Infect. 50, 206-209 (2005).
54. Ooi, N. et al. XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. J. Antimicrob. Chemother. 64, 735-740 (2009).
55. Ganzle, M. G. Reutericyclin: biological activity, mode of action, and potential applications. Appl. Microbiol. Biotechnol. 64, 326-332 (2004).
56. Hurdle, J. G., Yendapally, R., Sun, D. & Lee, R. E. Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections. Antimicrob. Agents Chemother. 53, 4028-4031 (2009).
57. Overhage, J. et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76, 4176-4182 (2008).
58. Flemming, K. et al. High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. J. Antimicrob. Chemother. 63, 136-145 (2009).
59. Benoit, M. R., Conant, C. G., Lonescu-Zanetti, C., Schwartz, M. & Matin, A. New device for high-throughput viability screening of flow biofilms. Appl. Environ. Microbiol. 76, 4136-4142 (2010).
60. Dowd, S. E. et al. Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol. 8, 43 (2008).
61. Yendapally, R., Hurdle, J. G., Carson, E. I., Lee, R. B. & Lee, R. E. N-substituted 3-acetyltetramic acid derivatives as antibacterial agents. J. Med. Chem. 51, 1487-1491 (2008).
62. Silverman, J. A., Mortin, L. I., Vanpraagh, A. D., Li, T. & Alder, J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191, 2149-2152 (2005).
63. Zhanel, G. G. et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70, 859-886 (2010).
64. Gotfried, M. H. et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob. Agents Chemother. 52, 92-97 (2008).
65. Van Bambeke, F., Saffran, J., Mingeot-Leclercq, M. P. & Tulkens, P. M. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob. Agents Chemother. 49, 1695-1700 (2005).
66. Van Bambeke, F., Mingeot-Leclercq, M. P., Struelens, M. J. & Tulkens, P. M. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol. Sci. 29, 124-134 (2008).
67. Mangili, A., Bica, I., Snydman, D. R. & Hamer, D. H. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40, 1058-1060 (2005).
68. Hayden, M. K. et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43, 5285-5287 (2005).
69. Mishra, N. N. et al. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53, 2312-2318 (2009).
70. Jones, T. et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52, 269-278 (2008).
71. Ernst, C. M. et al. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 5, e1000660 (2009).
72. Kosowska-Shick, K. et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53, 4217-4224 (2009).
73. Yang, S. J. et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200, 1916-1920 (2009).
74. Courvalin, P. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42, S25-S34 (2006).
75. Allen, N. E., LeTourneau, D. L. & Hobbs, J. N. Jr. Molecular interactions of a semisynthetic glycopeptide antibiotic with d-alanyl-d-alanine and d-alanyl-d-lactate residues. Antimicrob. Agents Chemother. 41, 66-71 (1997).
76. Allen, N. E. & Nicas, T. I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26, 511-532 (2003).
77. Arthur, M., Depardieu, F., Reynolds, P. & Courvalin, P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob. Agents Chemother. 43, 1875-1880 (1999).
78. Perichon, B. & Courvalin, P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53, 4580-4587 (2009).
79. Cholo, M. C., van Rensburg, E. & Anderson, R. Potassium uptake systems of Mycobacterium tuberculosis:genomic and protein organisation and potential roles in microbial pathogenesis and chemotherap. South Afr. J. Epidemiol. Infect. 23, 13-16 (2008).
80. Oliva, B., O'Neill, A. J., Miller, K., Stubbings, W. & Chopra, I. Anti-staphylococcal activity and mode of action of clofazimine. J. Antimicrob. Chemother. 53, 435-440 (2004).
81. Steel, H. C., Matlola, N. M. & Anderson, R. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J. Antimicrob. Chemother. 44, 209-216 (1999).
82. Cho, S. H. et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 1380-1385 (2007).
83. Adams, L. B., Sinha, I., Franzblau, S. G., Krahenbuhl, J. L. & Mehta, R. T. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob. Agents Chemother. 43, 1638-1643 (1999).
84. Reddy, V. M., O'Sullivan, J. F. & Gangadharam, P. R. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43, 615-623 (1999).
85. Purdy, G. E., Niederweis, M. & Russell, D. G. Decreased outer membrane permeability protects mycobacteria from killing by ubiquitin-derived peptides. Mol. Microbiol. 73, 844-857 (2009).
86. Hancock, R. E. & Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotech. 24, 1551-1557 (2006).
87. Blaser, M. J. & Kirschner, D. The equilibria that allow bacterial persistence in human hosts. Nature 449, 843-849 (2007).
88. Furukawa, S., Kuchma, S. L. & O'Toole, G. A. Keeping their options open: acute versus persistent infections. J. Bacteriol. 188, 1211-1217 (2006).
89. Bradshaw, C. S., Chen, M. Y. & Fairley, C. K. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS ONE 3, e3618 (2008).
90. Taylor-Robinson, D., Webster, A. D., Furr, P. M. & Asherson, G. L. Prolonged persistence of Mycoplasma pneumoniae in a patient with hypogammaglobulinaemia. J. Infect. 2, 171-175 (1980).
91. Abdelrahman, Y. M. & Belland, R. J. The chlamydial developmental cycle. FEMS Microbiol. Rev. 29, 949-959 (2005).
92. Donati, M. et al. Activity of cathelicidin peptides against Chlamydia spp. Antimicrob. Agents Chemother. 49, 1201-1202 (2005).
93. Yasin, B., Harwig, S. S., Lehrer, R. I. & Wagar, E. A. Susceptibility of Chlamydia trachomatis to protegrins and defensins. Infect. Immun. 64, 709-713 (1996).
94. Yasin, B., Pang, M., Lehrer, R. I. & Wagar, E. A. Activity of Novispirin G-10, a novel antimicrobial peptide against Chlamydia trachomatis and vaginosis-associated bacteria. Exp. Mol. Pathol. 74, 190-195 (2003).
95. Yasin, B., Pang, M. & Wagar, E. A. A cumulative experience examining the effect of natural and synthetic antimicrobial peptides vs. Chlamydia trachomatis. J. Pept. Res. 64, 65-71 (2004).
96. Lampe, M. F., Ballweber, L. M., Isaacs, C. E., Patton, D. L. & Stamm, W. E. Killing of Chlamydia trachomatis by novel antimicrobial lipids adapted from compounds in human breast milk. Antimicrob. Agents Chemother. 42, 1239-1244 (1998).
97. Park, N. et al. The cell-penetrating peptide, Pep-1, has activity against intracellular chlamydial growth but not extracellular forms of Chlamydia trachomatis. J. Antimicrob. Chemother. 63, 115-123 (2009).
98. Lazarev, V. N. et al. Induced expression of melittin, an antimicrobial peptide, inhibits infection by Chlamydia trachomatis and Mycoplasma hominis in a HeLa cell line. Int. J. Antimicrob. Agents 19, 133-137 (2002).
99. Lazarev, V. N. et al. Effect of induced expression of an antimicrobial peptide melittin on Chlamydia trachomatis and Mycoplasma hominis infections in vivo. Biochem. Biophys. Res. Commun. 338, 946-950 (2005).
100. Nir-Paz, R., Prevost, M. C., Nicolas, P., Blanchard, A. & Wroblewski, H. Susceptibilities of Mycoplasma fermentans and Mycoplasma hyorhinis to membrane-active peptides and enrofloxacin in human tissue cell cultures. Antimicrob. Agents Chemother. 46, 1218-1225 (2002).
101. Beven, L. & Wroblewski, H. Effect of natural amphipathic peptides on viability, membrane potential, cell shape and motility of mollicutes. Res. Microbiol. 148, 163-175 (1997).
102. Hatch, G. M. & McClarty, G. Phospholipid composition of purified Chlamydia trachomatis mimics that of the eucaryotic host cell. Infect. Immun. 66, 3727-3735 (1998).
103. Wylie, J. L., Hatch, G. M. & McClarty, G. Host cell phospholipids are trafficked to and then modified by Chlamydia trachomatis. J. Bacteriol. 179, 7233-7242 (1997).
104. Rotem, S. & Mor, A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 1788, 1582-1592 (2009).
105. Schobert, M. & Tielen, P. Contribution of oxygen-limiting conditions to persistent infection of Pseudomonas aeruginosa. Future Microbiol. 5, 603-621 (2010).
106. Hassett, D. J. et al. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv. Drug Deliv. Rev. 54, 1425-1443 (2002).
107. Kana, B. D. et al. in Mycobacterium: Genomics and Molecular Biology (eds Parish, T. & Brown, A.) 35-64 (Caister Academic, Norfolk, UK, 2010).
108. Biswas, L., Biswas, R., Schlag, M., Bertram, R. & Gotz, F. Small-colony variant selection as a survival strategy for Staphylococcus aureus in the presence of Pseudomonas aeruginosa. Appl. Environ. Microbiol. 75, 6910-6912 (2009).
109. Besier, S. et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J. Clin. Microbiol. 45, 168-172 (2007).
110. Alvarez-Ortega, C. & Harwood, C. S. Responses of Pseudomonas aeruginosa to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration. Mol. Microbiol. 65, 153-165 (2007).
111. Schlag, S., Nerz, C., Birkenstock, T. A., Altenberend, F. & Gotz, F. Inhibition of staphylococcal biofilm formation by nitrite. J. Bacteriol. 189, 7911-7919 (2007).
112. Boshoff, H. I. et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279, 40174-40184 (2004).
113. Karakousis, P. C. et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J. Exp. Med. 200, 647-657 (2004).
114. 1 ATPase are novel live attenuated vaccine strains. Vaccine 28, 940-949 (2010).
115. Dhiman, R. K. et al. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol. Microbiol. 72, 85-97 (2009).
116. Dekkers, L. C. et al. Role of the O-antigen of lipopolysaccharide, and possible roles of growth rate and of NADH:ubiquinone oxidoreductase (nuo) in competitive tomato root-tip colonization by Pseudomonas fluorescens WCS365. Mol. Plant Microbe Interact. 11, 763-771 (1998).
117. Zhu, L. et al. Characterization of mRNA interferases from Mycobacterium tuberculosis. J. Biol. Chem. 281, 18638-18643 (2006).
118. Melo, A. M., Bandeiras, T. M. & Teixeira, M. New insights into type II NAD(P)H:quinone oxidoreductases. Microbiol. Mol. Biol. Rev. 68, 603-616 (2004).
119. Richardson, A. R., Libby, S. J. & Fang, F. C. A nitric oxide-inducible lactate dehydrogenase enables Staphylococcus aureus to resist innate immunity. Science 319, 1672-1676 (2008).
120. Somerville, G. A. & Proctor, R. A. At the crossroads of bacterial metabolism and virulence factor synthesis in staphylococci. Microbiol. Mol. Biol. Rev. 73, 233-248 (2009).
121. Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A. & Collins, J. J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130, 797-810 (2007).
122. Fuchs, S., Pane-Farre, J., Kohler, C., Hecker, M. & Engelmann, S. Anaerobic gene expression in Staphylococcus aureus. J. Bacteriol. 189, 4275-4289 (2007).
123. Bald, D. & Koul, A. Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol. Lett. 308, 1-7 (2010).
124. Wade, M. M. & Zhang, Y. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J. Med. Microbiol. 53, 769-773 (2004).
125. Zhang, Y., Wade, M. M., Scorpio, A., Zhang, H. & Sun, Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52, 790-795 (2003).
126. Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273-25280 (2008).
127. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
128. Petrella, S. et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother. 50, 2853-2856 (2006).
129. Ibrahim, M. et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother. 51, 1011-1015 (2007).
130. Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397-2405 (2009).
131. Rustomjee, R. et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52, 2831-2835 (2008).
132. Lenaerts, A. J. et al. Location of persisting mycobacteria in the guinea pig model of tuberculosis revealed by R207910. Antimicrob. Agents Chemother. 51, 3338-3345 (2007).
133. Deb, C. et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS ONE 4, e6077 (2009).
134. Upadhayaya, R. S. et al. Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. Bioorg. Med. Chem. 17, 2830-2841 (2009).
135. Yano, T., Li, L. S., Weinstein, E., Teh, J. S. & Rubin, H. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J. Biol. Chem. 281, 11456-11463 (2006).
136. Weinstein, E. A. et al. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Nat. Acad. Sci. USA 102, 4548-4553 (2005).
137. Amaral, L., Boeree, M. J., Gillespie, S. H., Udwadia, Z. F. & van Soolingen, D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int. J. Antimicrob. Agents 35, 524-526 (2010).
138. Ordway, D., Viveiros, M., Leandro, C., Arroz, M. J. & Amaral, L. Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. Int. J. Antimicrob. Agents 20, 34-43 (2002).
139. Xie, Z., Siddiqi, N. & Rubin, E. J. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 49, 4778-4780 (2005).
140. Mogi, T. et al. Identification of new inhibitors for alternative NADH dehydrogenase (NDH-II). FEMS Microbiol. Lett. 291, 157-161 (2009).
141. Mogi, T. et al. Antibiotics LL-Z1272 identified as novel inhibitors discriminating bacterial and mitochondrial quinol oxidases. Biochim. Biophys. Acta 1787, 129-133 (2009).
142. Cardoso, R. F. et al. Characterization of ndh gene of isoniazid resistant and susceptible Mycobacterium tuberculosis isolates from Brazil. Mem. Inst. Oswaldo Cruz 102, 59-61 (2007).
143. Van Den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J. & Aarnoutse, R. E. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother. 53, 849-862 (2009).
144. De Carvalho, L. P., Lin, G., Jiang, X. & Nathan, C. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J. Med. Chem. 52, 5789-5792 (2009).
145. Hurdle, J. G. et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemother. 62, 1037-1045 (2008).
146. Manjunatha, U., Boshoff, H. I. & Barry, C. E. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215-218 (2009).
147. Sisson, G. et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 46, 2116-2123 (2002).
148. Shamir, E. R. et al. Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae. Antimicrob. Agents Chemother. 54, 1526-1533 (2010).
149. Tchouaffi-Nana, F. et al. Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces. Antimicrob. Agents Chemother. 54, 2767-2774(2010).
150. Mathur, T., Bhateja, P., Pandya, M., Fatma, T. & Rattan, A. In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria. Int. J. Antimicrob. Agents 24, 369-373 (2004).
151. Kalia, V. et al. Mode of action of ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob. Agents Chemother. 53, 1427-1433 (2009).
152. Smith, P. A. & Romesberg, F. E. Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. Nature Chem. Biol. 3, 549-556 (2007).
153. Hansen, S., Lewis, K. & Vulic, M. Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. Antimicrob. Agents Chemother. 52, 2718-2726 (2008).
154. Vazquez-Laslop, N., Lee, H. & Neyfakh, A. A. Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J. Bacteriol. 188, 3494-3497 (2006).
155. O'Neill, A. J., Miller, K., Oliva, B. & Chopra, I. Comparison of assays for detection of agents causing membrane damage in Staphylococcus aureus. J. Antimicrob. Chemother. 54, 1127-1129 (2004).
156. Walsh, T. J. et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42, 2391-2398 (1998).
157. Carlson, R. P., Taffs, R., Davison, W. M. & Stewart, P. S. Anti-biofilm properties of chitosan-coated surfaces. J. Biomater. Sci. Polym. Ed. 19, 1035-1046 (2008).
158. Savage, P. B. et al. in Microbial Surfaces: Structure, Interactions, and Reactivity (eds Camesano, T. A. & Mello, C. M.) 65-78 (American Chemical Society, Washington DC, 2008).
159. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Rev. Microbiol. 3, 238-250 (2005).
160. Hawkey, P. M. Pre-clinical experience with daptomycin. J. Antimicrob. Chemother. 62, 7-14 (2008).
161. Epand, R. F., Pollard, J. E., Wright, J., Savage, P. B. & Epand, R. M. Depolarization, bacterial membrane composition and the antimicrobial action of ceragenins. Antimicrob. Agents Chemother. 54, 3708-3713 (2010).
162. Chin, J. N., Rybak, M. J., Cheung, C. M. & Savage, P. B. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51, 1268-1273 (2007).
163. Coates, T., Bax, R. & Coates, A. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J. Antimicrob. Chemother. 64, 9-15 (2009).
164. Budha, N. et al. Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. AAPS J. 10, 157-165 (2008).
165. Tangallapally, R. P., Yendapally, R., Daniels, A. J., Lee, R. E. & Lee, R. E. Nitrofurans as novel anti-tuberculosis agents: identification, development and evaluation. Curr. Top. Med. Chem. 7, 509-526 (2007).
166. Ballard, T. E. et al. Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide. Bioorg. Med. Chem. Lett. 20, 3537-3539 (2010).